Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1295232.RAuf8EphlvwR-hl3rwvn7HkafIx2dZz1MVWoursOa7K4g130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1295232.RAuf8EphlvwR-hl3rwvn7HkafIx2dZz1MVWoursOa7K4g130_assertion type Assertion NP1295232.RAuf8EphlvwR-hl3rwvn7HkafIx2dZz1MVWoursOa7K4g130_head.
- NP1295232.RAuf8EphlvwR-hl3rwvn7HkafIx2dZz1MVWoursOa7K4g130_assertion description "[The various reports of dramatic and prolonged responses in brain metastases patients treated with EGFR and ALK TKIs suggest that these agents may be a valid treatment option for patients with asymptomatic brain metastases from NSCLC, especially for those with EGFR-activating mutations or harboring ALK rearrangement.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1295232.RAuf8EphlvwR-hl3rwvn7HkafIx2dZz1MVWoursOa7K4g130_provenance.
- NP1295232.RAuf8EphlvwR-hl3rwvn7HkafIx2dZz1MVWoursOa7K4g130_assertion evidence source_evidence_literature NP1295232.RAuf8EphlvwR-hl3rwvn7HkafIx2dZz1MVWoursOa7K4g130_provenance.
- NP1295232.RAuf8EphlvwR-hl3rwvn7HkafIx2dZz1MVWoursOa7K4g130_assertion SIO_000772 26504000 NP1295232.RAuf8EphlvwR-hl3rwvn7HkafIx2dZz1MVWoursOa7K4g130_provenance.
- NP1295232.RAuf8EphlvwR-hl3rwvn7HkafIx2dZz1MVWoursOa7K4g130_assertion wasDerivedFrom befree-2016 NP1295232.RAuf8EphlvwR-hl3rwvn7HkafIx2dZz1MVWoursOa7K4g130_provenance.
- NP1295232.RAuf8EphlvwR-hl3rwvn7HkafIx2dZz1MVWoursOa7K4g130_assertion wasGeneratedBy ECO_0000203 NP1295232.RAuf8EphlvwR-hl3rwvn7HkafIx2dZz1MVWoursOa7K4g130_provenance.